Relamorelin
Fat LossInvestigational ghrelin analogEmerging
Pentapeptide ghrelin analog studied for diabetic gastroparesis. Development has been mixed; not FDA-approved.
For research use only.
Key Facts
- CAS
- 661472-41-9
- Molecular Weight (MW)
- 790.97 g/mol
- Half-life
- Not firmly established in public sources; studied as short-acting sc peptide
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Per study
- Last updated
- 8/23/2026
- Targets
- GHSR
Overview
Pentapeptide ghrelin analog studied for diabetic gastroparesis. Development has been mixed; not FDA-approved.
Protocol
- Dosage Range
- Per trial protocol
- Frequency
- Per study
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
GHSR agonist that accelerates gastric emptying and can raise GH; studied to reduce nausea and improve emptying in diabetes.
Targets
GHSR
Studies
- Relamorelin diabetic gastroparesis— Journal/year not available
Benefits
Gastroparesis research candidate
Potential Side Effects
- Hyperglycemia
- Hunger
- GI effects
References
- PMID 26923550External link · Year —
- WADA Prohibited List 2026External link · Year —